Conatus Pharmaceuticals Stock Price, News & Analysis (NASDAQ:CNAT)

$4.61 -0.08 (-1.71 %)
(As of 01/16/2018 04:00 PM ET)
Previous Close$4.61
Today's Range$4.50 - $4.79
52-Week Range$3.88 - $9.40
Volume233,575 shs
Average Volume269,340 shs
Market Capitalization$136.22 million
P/E Ratio-5.69
Dividend YieldN/A
Beta1.1

About Conatus Pharmaceuticals (NASDAQ:CNAT)

Conatus Pharmaceuticals logoConatus Pharmaceuticals Inc. is a biotechnology company. The Company focuses on the development and commercialization of medicines to treat liver disease. The Company operates through commercialization and development of pharmaceutical products segment. The Company is engaged in developing emricasan, which is an orally active pan-caspase protease inhibitor for the treatment of patients with chronic liver disease. Emricasan has the potential to interrupt the progression of liver disease and provide treatment options in multiple areas of liver disease. Emricasan is designed to slow or halt the progression of chronic liver disease caused by fibrosis and cirrhosis. Emricasan works by inhibiting caspases, which are a family of related enzymes that plays as modulators of critical cellular functions, including functions that result in apoptosis and inflammation.

Receive CNAT News and Ratings via Email

Sign-up to receive the latest news and ratings for CNAT and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Bio Therapeutic Drugs
Sub-IndustryN/A
SectorHealthcare
SymbolNASDAQ:CNAT
CUSIPN/A
Phone+1-858-3762600

Debt

Debt-to-Equity Ratio0.41%
Current Ratio2.69%
Quick Ratio2.69%

Price-To-Earnings

Trailing P/E Ratio-5.69135802469136
Forward P/E Ratio-7.09
P/E GrowthN/A

Sales & Book Value

Annual Sales$800,000.00
Price / Sales172.88
Cash FlowN/A
Price / CashN/A
Book Value$0.84 per share
Price / Book5.49

Profitability

Trailing EPS($0.81)
Net Income$-29,730,000.00
Net Margins-80.98%
Return on Equity-83.02%
Return on Assets-25.04%

Miscellaneous

Employees27
Outstanding Shares30,000,000

Conatus Pharmaceuticals (NASDAQ:CNAT) Frequently Asked Questions

What is Conatus Pharmaceuticals' stock symbol?

Conatus Pharmaceuticals trades on the NASDAQ under the ticker symbol "CNAT."

How were Conatus Pharmaceuticals' earnings last quarter?

Conatus Pharmaceuticals Inc (NASDAQ:CNAT) issued its earnings results on Wednesday, November, 1st. The biotechnology company reported ($0.13) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.05) by $0.08. The biotechnology company had revenue of $9.57 million for the quarter, compared to analyst estimates of $16.06 million. Conatus Pharmaceuticals had a negative return on equity of 83.02% and a negative net margin of 80.98%. During the same quarter in the prior year, the firm earned ($0.31) earnings per share. View Conatus Pharmaceuticals' Earnings History.

When will Conatus Pharmaceuticals make its next earnings announcement?

Conatus Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Tuesday, March, 13th 2018. View Earnings Estimates for Conatus Pharmaceuticals.

Where is Conatus Pharmaceuticals' stock going? Where will Conatus Pharmaceuticals' stock price be in 2018?

5 Wall Street analysts have issued twelve-month price objectives for Conatus Pharmaceuticals' shares. Their predictions range from $10.00 to $17.00. On average, they anticipate Conatus Pharmaceuticals' stock price to reach $14.00 in the next twelve months. View Analyst Ratings for Conatus Pharmaceuticals.

What are Wall Street analysts saying about Conatus Pharmaceuticals stock?

Here are some recent quotes from research analysts about Conatus Pharmaceuticals stock:

  • 1. According to Zacks Investment Research, "Conatus presently has no approved product in its portfolio. Though the company is progressing well with its lead Candidate, emricasan for chronic liver diseases, it is still several years away from entering the market. Any development/regulatory setback of emricasan could hamper Conatus’ prospects. The company is alos conducting several phase IIb studies on emricasan, targeting different types of NASH patient populations. Notably, several companies are working on developing treatments for NASH, which might make the market competitive for emricasan. The stock has underperformed the industry in the last one year. However, we are encouraged by Conatus’ agreement with Novartis for emricasan, as it not only lends expertise to the company, but also provides it with funds to develop emricasan." (1/16/2018)
  • 2. Aegis analysts commented, "We believe that Novartis will likely exercise its option for worldwide exclusive rights to Emricasan. Potential Combination Products. Under the agreement, Novartis’ option includes the ability to develop products using either Emricasan as the sole active ingredient or in combination with other compounds in its pipeline (e.g., farnesoid X). The tiered royalties payable to Conatus for these potential combination products range from high-single digits to mid-teens and are subject to certain reductions." (3/16/2017)
  • 3. FBR & Co analysts commented, "We think the strong pairing formed when Conatus Pharmaceuticals signed an option, collaboration, and licensing agreement with Novartis (NVS) firmly de-risked the path for completing clinical development of CNAT's Phase III ready liver disease drug emricasan, which is the most clinically advanced drug candidate in liver cirrhosis. In particular, we look for CNAT to benefit from collaborative synergies with NVS's expertise in liver disease research, and its track record of success in drug development and commercialization. As it is now a key new program in NVS's pipeline of $1B-plus potential product candidates, we also think this deal validates the value of emricasan, with the $650M deal recognition of emricasan's potential application in liver diseases with different etiologies. Therefore, we reiterate our Outperform rating." (3/15/2017)

Who are some of Conatus Pharmaceuticals' key competitors?

Who are Conatus Pharmaceuticals' key executives?

Conatus Pharmaceuticals' management team includes the folowing people:

  • David F. Hale, Independent Chairman of the Board (Age 67)
  • Steven J. Mento Ph.D., President, Chief Executive Officer, Director (Age 65)
  • Keith W. Marshall, Chief Financial Officer, Principal Financial Officer, Chief Operating Officer, Executive Vice President
  • Alfred P. Spada Ph.D., Executive Vice President - Research & Development, Chief Scientific Officer (Age 57)
  • David T. Hagerty M.D., Executive Vice President, Clinical Development (Age 60)
  • Daniel L. Ripley, Senior Vice President - Business Development, Program and Alliance Management
  • Edward F. Smith III., Ph.D., Senior Vice President - Regulatory Affairs and Quality Assurance
  • Michelle L Vandertie, Acting Principal Accounting Officer (Age 53)
  • Daniel L. Kisner M.D., Additional Independent Director (Age 70)
  • Preston S. Klassen M.D., Additional Independent Director (Age 48)

How do I buy Conatus Pharmaceuticals stock?

Shares of Conatus Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Conatus Pharmaceuticals' stock price today?

One share of Conatus Pharmaceuticals stock can currently be purchased for approximately $4.61.

How big of a company is Conatus Pharmaceuticals?

Conatus Pharmaceuticals has a market capitalization of $136.22 million and generates $800,000.00 in revenue each year. The biotechnology company earns $-29,730,000.00 in net income (profit) each year or ($0.81) on an earnings per share basis. Conatus Pharmaceuticals employs 27 workers across the globe.

How can I contact Conatus Pharmaceuticals?

Conatus Pharmaceuticals' mailing address is 16745 W Bernardo Dr Ste 200, SAN DIEGO, CA 92127-1906, United States. The biotechnology company can be reached via phone at +1-858-3762600 or via email at [email protected]


MarketBeat Community Rating for Conatus Pharmaceuticals (CNAT)

Community Ranking:  3.3 out of 5 (star star star)
Outperform Votes:  239 (Vote Outperform)
Underperform Votes:  118 (Vote Underperform)
Total Votes:  357
MarketBeat's community ratings are surveys of what our community members think about Conatus Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Conatus Pharmaceuticals (NASDAQ:CNAT) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $14.00$16.00$16.17$14.50
Price Target Upside: 205.01% upside248.58% upside187.66% upside158.93% upside

Conatus Pharmaceuticals (NASDAQ:CNAT) Consensus Price Target History

Price Target History for Conatus Pharmaceuticals (NASDAQ:CNAT)

Conatus Pharmaceuticals (NASDAQ:CNAT) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/2/2017HC WainwrightReiterated RatingBuy -> Buy$18.00 -> $17.00N/AView Rating Details
10/6/2017Seaport Global SecuritiesReiterated RatingBuy$16.00N/AView Rating Details
8/3/2017Stifel NicolausReiterated RatingBuy$10.00HighView Rating Details
5/15/2017AegisReiterated RatingBuy$11.00N/AView Rating Details
3/15/2017FBR & CoReiterated RatingOutperform$16.00HighView Rating Details
12/23/2016SunTrust BanksReiterated RatingBuy$17.00 -> $26.00N/AView Rating Details
11/9/2016JMP SecuritiesReiterated RatingBuyN/AView Rating Details
10/4/2016Brean CapitalReiterated RatingBuy$7.00N/AView Rating Details
7/1/2016Roth CapitalInitiated CoverageBuy -> BuyN/AView Rating Details
(Data available from 1/16/2016 forward)

Earnings

Conatus Pharmaceuticals (NASDAQ:CNAT) Earnings History and Estimates Chart

Earnings by Quarter for Conatus Pharmaceuticals (NASDAQ:CNAT)

Conatus Pharmaceuticals (NASDAQ CNAT) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/13/2018($0.17)N/AView Earnings Details
11/1/2017Q3 2017($0.05)($0.13)$16.06 million$9.57 millionViewN/AView Earnings Details
8/2/2017Q2 2017($0.17)($0.19)$9.33 million$10.00 millionViewListenView Earnings Details
5/4/2017Q1 2017($0.34)($0.14)$5.88 million$7.00 millionViewListenView Earnings Details
3/15/2017Q4 2016($0.32)($0.35)$0.80 millionViewN/AView Earnings Details
11/8/2016Q3($0.34)($0.31)ViewListenView Earnings Details
8/3/2016Q216($0.38)($0.30)ViewN/AView Earnings Details
5/5/2016Q116($0.35)($0.35)ViewN/AView Earnings Details
3/9/2016Q4($0.37)($0.30)ViewListenView Earnings Details
11/4/2015Q315($0.38)($0.31)ViewN/AView Earnings Details
8/5/2015Q215($0.34)($0.31)ViewN/AView Earnings Details
5/7/2015Q115($0.35)($0.38)ViewListenView Earnings Details
3/11/2015Q414($0.49)($0.34)ViewListenView Earnings Details
11/12/2014Q3($0.43)($0.42)ViewN/AView Earnings Details
8/13/2014Q214($0.39)($0.34)ViewListenView Earnings Details
5/13/2014Q1($0.34)($0.34)ViewN/AView Earnings Details
3/27/2014($0.27)($0.33)ViewN/AView Earnings Details
11/14/2013Q3($0.20)($0.28)ViewListenView Earnings Details
9/9/2013Q2 2013($0.22)$0.16ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Conatus Pharmaceuticals (NASDAQ:CNAT) Earnings Estimates

Current Year EPS Consensus Estimate: $-0.65 EPS
Next Year EPS Consensus Estimate: $0.62 EPS

Dividends

Dividend History for Conatus Pharmaceuticals (NASDAQ:CNAT)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Conatus Pharmaceuticals (NASDAQ CNAT) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 13.90%
Institutional Ownership Percentage: 36.84%
Insider Trades by Quarter for Conatus Pharmaceuticals (NASDAQ:CNAT)
Insider Trades by Quarter for Conatus Pharmaceuticals (NASDAQ:CNAT)

Conatus Pharmaceuticals (NASDAQ CNAT) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
4/8/2015Daniel L KisnerDirectorBuy4,000$5.75$23,000.00View SEC Filing  
7/30/2013David F HaleDirectorBuy2,588$11.00$28,468.00View SEC Filing  
7/30/2013Luke EvninMajor ShareholderBuy165,265$11.00$1,817,915.00View SEC Filing  
7/30/2013Steven J MentoCEOBuy13,800$11.00$151,800.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Conatus Pharmaceuticals (NASDAQ CNAT) News Headlines

Source:
DateHeadline
Conatus Pharmaceuticals (CNAT) Downgraded to Sell at Zacks Investment ResearchConatus Pharmaceuticals (CNAT) Downgraded to Sell at Zacks Investment Research
www.americanbankingnews.com - January 16 at 12:44 PM
 Analysts Anticipate Conatus Pharmaceuticals Inc (CNAT) Will Post Quarterly Sales of $9.50 Million Analysts Anticipate Conatus Pharmaceuticals Inc (CNAT) Will Post Quarterly Sales of $9.50 Million
www.americanbankingnews.com - January 11 at 8:14 AM
Head to Head Review: Conatus Pharmaceuticals (CNAT) vs. Trevena (TRVN)Head to Head Review: Conatus Pharmaceuticals (CNAT) vs. Trevena (TRVN)
www.americanbankingnews.com - January 10 at 5:10 AM
Conatus Pharmaceuticals Inc (CNAT) Given Average Rating of "Buy" by AnalystsConatus Pharmaceuticals Inc (CNAT) Given Average Rating of "Buy" by Analysts
www.americanbankingnews.com - January 9 at 11:34 AM
Zacks: Analysts Expect Conatus Pharmaceuticals Inc (CNAT) to Post -$0.17 Earnings Per ShareZacks: Analysts Expect Conatus Pharmaceuticals Inc (CNAT) to Post -$0.17 Earnings Per Share
www.americanbankingnews.com - January 9 at 11:34 AM
Conatus Pharmaceuticals Inc (CNAT) Receives Consensus Recommendation of "Buy" from BrokeragesConatus Pharmaceuticals Inc (CNAT) Receives Consensus Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - December 15 at 12:26 PM
Your Daily Pharma Scoop: Conatus Looks Undervalued, Teva Announces Restructuring, Bristol-Myers Signs Licensing ... - Seeking AlphaYour Daily Pharma Scoop: Conatus Looks Undervalued, Teva Announces Restructuring, Bristol-Myers Signs Licensing ... - Seeking Alpha
seekingalpha.com - December 15 at 9:58 AM
Conatus: Likely To Dash Ahead Of NASH Data - Seeking AlphaConatus: Likely To Dash Ahead Of NASH Data - Seeking Alpha
seekingalpha.com - December 15 at 9:58 AM
Conatus Pharmaceuticals Inc (CNAT) Expected to Announce Quarterly Sales of $9.50 MillionConatus Pharmaceuticals Inc (CNAT) Expected to Announce Quarterly Sales of $9.50 Million
www.americanbankingnews.com - December 8 at 12:06 PM
$9.50 Million in Sales Expected for Conatus Pharmaceuticals Inc. (CNAT) This Quarter$9.50 Million in Sales Expected for Conatus Pharmaceuticals Inc. (CNAT) This Quarter
www.americanbankingnews.com - November 20 at 12:40 PM
Conatus Pharmaceuticals Inc. (CNAT) Given Consensus Rating of "Buy" by BrokeragesConatus Pharmaceuticals Inc. (CNAT) Given Consensus Rating of "Buy" by Brokerages
www.americanbankingnews.com - November 20 at 7:54 AM
 Analysts Anticipate Conatus Pharmaceuticals Inc. (CNAT) Will Announce Earnings of -$0.17 Per Share Analysts Anticipate Conatus Pharmaceuticals Inc. (CNAT) Will Announce Earnings of -$0.17 Per Share
www.americanbankingnews.com - November 18 at 1:30 PM
Commit To Buy Conatus Pharmaceuticals At $2.50, Earn 9.4% Annualized Using OptionsCommit To Buy Conatus Pharmaceuticals At $2.50, Earn 9.4% Annualized Using Options
www.thestreet.com - November 16 at 12:58 PM
Short Interest in Conatus Pharmaceuticals Inc. (CNAT) Declines By 30.6%Short Interest in Conatus Pharmaceuticals Inc. (CNAT) Declines By 30.6%
www.americanbankingnews.com - November 14 at 1:02 AM
Short Interest Decreases By 30.6% For CNATShort Interest Decreases By 30.6% For CNAT
www.thestreet.com - November 11 at 5:13 PM
Conatus Pharmaceuticals Inc. (CNAT) Forecasted to Earn FY2017 Earnings of ($0.60) Per ShareConatus Pharmaceuticals Inc. (CNAT) Forecasted to Earn FY2017 Earnings of ($0.60) Per Share
www.americanbankingnews.com - November 9 at 8:30 AM
Conatus to Present at Stifel Healthcare ConferenceConatus to Present at Stifel Healthcare Conference
finance.yahoo.com - November 7 at 10:27 PM
Conatus Pharmaceuticals Inc. (CNAT) Forecasted to Earn FY2017 Earnings of ($0.47) Per ShareConatus Pharmaceuticals Inc. (CNAT) Forecasted to Earn FY2017 Earnings of ($0.47) Per Share
www.americanbankingnews.com - November 6 at 6:36 AM
FY2017 Earnings Forecast for Conatus Pharmaceuticals Inc. Issued By Seaport Global Securities (CNAT)FY2017 Earnings Forecast for Conatus Pharmaceuticals Inc. Issued By Seaport Global Securities (CNAT)
www.americanbankingnews.com - November 6 at 6:36 AM
Conatus (CNAT) Loss Wider Than Expected in Q3, Sales MissConatus (CNAT) Loss Wider Than Expected in Q3, Sales Miss
finance.yahoo.com - November 2 at 6:08 PM
Conatus Pharmaceuticals (CNAT) CEO Steve Mento on Q3 2017 Results - Earnings Call Transcript - Seeking AlphaConatus Pharmaceuticals' (CNAT) CEO Steve Mento on Q3 2017 Results - Earnings Call Transcript - Seeking Alpha
seekingalpha.com - November 2 at 4:19 AM
Conatus reports 3Q lossConatus reports 3Q loss
finance.yahoo.com - November 1 at 11:17 PM
Conatus Pharmaceuticals Inc. to Host Earnings CallConatus Pharmaceuticals Inc. to Host Earnings Call
finance.yahoo.com - November 1 at 6:13 PM
Conatus Pharmaceuticals Reports Third Quarter 2017 Financial Results and Program UpdatesConatus Pharmaceuticals Reports Third Quarter 2017 Financial Results and Program Updates
finance.yahoo.com - November 1 at 6:13 PM
Conatus Pharmaceuticals Inc. (CNAT) Issues Quarterly  Earnings Results, Beats Estimates By $0.02 EPSConatus Pharmaceuticals Inc. (CNAT) Issues Quarterly Earnings Results, Beats Estimates By $0.02 EPS
www.americanbankingnews.com - November 1 at 5:46 PM
Zacks: Analysts Expect Conatus Pharmaceuticals Inc. (CNAT) Will Announce Quarterly Sales of $16.06 MillionZacks: Analysts Expect Conatus Pharmaceuticals Inc. (CNAT) Will Announce Quarterly Sales of $16.06 Million
www.americanbankingnews.com - October 30 at 2:02 AM
Conatus Pharmaceuticals Inc (CNAT) Expected to Announce Earnings of -$0.05 Per ShareConatus Pharmaceuticals Inc (CNAT) Expected to Announce Earnings of -$0.05 Per Share
www.americanbankingnews.com - October 28 at 11:12 PM
Conatus Pharmaceuticals Inc. (CNAT) to Release Quarterly Earnings on WednesdayConatus Pharmaceuticals Inc. (CNAT) to Release Quarterly Earnings on Wednesday
www.americanbankingnews.com - October 26 at 1:18 PM
Conatus Pharmaceuticals Inc. (CNAT) Given Average Rating of "Buy" by BrokeragesConatus Pharmaceuticals Inc. (CNAT) Given Average Rating of "Buy" by Brokerages
www.americanbankingnews.com - October 26 at 7:58 AM
Conatus Pharmaceuticals to Report Third Quarter 2017 Financial Results - GlobeNewswire (press release)Conatus Pharmaceuticals to Report Third Quarter 2017 Financial Results - GlobeNewswire (press release)
globenewswire.com - October 25 at 11:55 PM
Conatus Pharmaceuticals to Report Third Quarter 2017 Financial ResultsConatus Pharmaceuticals to Report Third Quarter 2017 Financial Results
feeds.benzinga.com - October 25 at 8:03 AM
Oversold Conditions For Conatus Pharmaceuticals (CNAT)Oversold Conditions For Conatus Pharmaceuticals (CNAT)
www.thestreet.com - October 24 at 7:42 PM
Conatus Entrusts Keith W. Marshall With Key Management Roles - NasdaqConatus Entrusts Keith W. Marshall With Key Management Roles - Nasdaq
www.nasdaq.com - October 21 at 4:54 AM
Conatus Pharmaceuticals (CNAT) Announces Poster Presentation ... - StreetInsider.comConatus Pharmaceuticals (CNAT) Announces Poster Presentation ... - StreetInsider.com
www.streetinsider.com - October 21 at 4:54 AM
Conatus Liver Disease Drug Gets Orphan Drug Tag in the EUConatus' Liver Disease Drug Gets Orphan Drug Tag in the EU
finance.yahoo.com - October 20 at 6:49 PM
Conatus Pharmaceuticals Announces Poster Presentation at AASLD Annual MeetingConatus Pharmaceuticals Announces Poster Presentation at AASLD Annual Meeting
finance.yahoo.com - October 20 at 6:49 PM
Conatus' Liver Disease Drug Gets Orphan Drug Tag in the EUConatus' Liver Disease Drug Gets Orphan Drug Tag in the EU
finance.yahoo.com - October 20 at 6:49 PM
Conatus Pharmaceuticals (CNAT) Granted Orphan Drug Designation for IDN-7314 for the Treatment of PSCConatus Pharmaceuticals (CNAT) Granted Orphan Drug Designation for IDN-7314 for the Treatment of PSC
www.streetinsider.com - October 19 at 5:51 PM
FDA Blesses 2nd CAR-T Cell Therapy, NVO One Step Away From Approval, AKTX SlumpsFDA Blesses 2nd CAR-T Cell Therapy, NVO One Step Away From Approval, AKTX Slumps
www.rttnews.com - October 19 at 4:45 AM
13 Stocks Moving In Wednesdays After-Hours Session - Benzinga13 Stocks Moving In Wednesday's After-Hours Session - Benzinga
www.benzinga.com - October 18 at 11:44 PM
Conatus Pharmaceuticals (CNAT) Granted Orphan Drug Designation for IDN-7314 for the Treatment of PSC - StreetInsider.comConatus Pharmaceuticals (CNAT) Granted Orphan Drug Designation for IDN-7314 for the Treatment of PSC - StreetInsider.com
www.streetinsider.com - October 18 at 11:44 PM
EMA Grants Conatus Orphan Drug Designation for IDN-7314 for the Treatment of PSCEMA Grants Conatus Orphan Drug Designation for IDN-7314 for the Treatment of PSC
finance.yahoo.com - October 18 at 6:44 PM
Technical Insights on Biotech Stocks -- Conatus Pharma, Immunomedics, INSYS Therapeutics, and InVivo TherapeuticsTechnical Insights on Biotech Stocks -- Conatus Pharma, Immunomedics, INSYS Therapeutics, and InVivo Therapeutics
www.bizjournals.com - October 17 at 6:05 PM
Non-Alcoholic Steatohepatitis 2017 Progress Update - NasdaqNon-Alcoholic Steatohepatitis 2017 Progress Update - Nasdaq
www.nasdaq.com - October 12 at 11:10 PM
$12.80 Million in Sales Expected for Conatus Pharmaceuticals Inc. (CNAT) This Quarter$12.80 Million in Sales Expected for Conatus Pharmaceuticals Inc. (CNAT) This Quarter
www.americanbankingnews.com - October 11 at 3:38 AM
 Analysts Anticipate Conatus Pharmaceuticals Inc. (CNAT) Will Announce Earnings of $0.02 Per Share Analysts Anticipate Conatus Pharmaceuticals Inc. (CNAT) Will Announce Earnings of $0.02 Per Share
www.americanbankingnews.com - October 9 at 6:26 PM
Conatus Pharmaceuticals Inc. (CNAT) Earns Buy Rating from Analysts at Seaport Global SecuritiesConatus Pharmaceuticals Inc. (CNAT) Earns Buy Rating from Analysts at Seaport Global Securities
www.americanbankingnews.com - October 7 at 2:58 PM
12 Biggest Mid-Day Gainers For Friday | Benzinga - Benzinga12 Biggest Mid-Day Gainers For Friday | Benzinga - Benzinga
www.benzinga.com - October 6 at 10:42 PM
Conatus Pharmaceuticals Inc (CNAT) Receives Average Recommendation of "Buy" from AnalystsConatus Pharmaceuticals Inc (CNAT) Receives Average Recommendation of "Buy" from Analysts
www.americanbankingnews.com - October 1 at 8:50 AM
Will Conatus Liver Disease Candidate Drive Long-Term Growth?Will Conatus Liver Disease Candidate Drive Long-Term Growth?
www.zacks.com - September 28 at 5:14 PM

SEC Filings

Conatus Pharmaceuticals (NASDAQ:CNAT) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Conatus Pharmaceuticals (NASDAQ:CNAT) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Conatus Pharmaceuticals (NASDAQ CNAT) Stock Chart for Tuesday, January, 16, 2018

Loading chart…

This page was last updated on 1/16/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.